Cancer Family
Malignant Mesothelioma
CI-CAN-00000240Explore in graph →
Top-level96 active trials4 approved drugs11 evidence items
- NCIt
- C4456
- ICD-10
- C45
- DOID
- 1790
- MeSH
- D000086002
- MeSH
- D008654
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000240Explore in graph →
Clinical trials
478 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (81)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06654050 | Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT05582031 |
| Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers(REFIT-MSS) |
| withdrawn |
| Phase 2 |
| 0 |
| Translational Research in OncologyOTHER |
| 0 |
| Jun 7, 2023 |
| clinicaltrials |
| NCT03786419 | A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma | withdrawn | Phase 2 | 0 | Health Pharma Professional ResearchOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT00668499 | A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | May 21, 2014 | clinicaltrials |
| NCT01105390 | AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Aug 2, 2013 | clinicaltrials |
| NCT01353482 | A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma(MESO-02) | withdrawn | Phase 1 / Phase 2 | 0 | University College, LondonOTHER | 0 | Mar 22, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Mar 17, 2026source: clinicaltrials